H. Lee Moffitt Cancer Center and Research Institute
607
89
160
324
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
15.7%
95 terminated/withdrawn out of 607 trials
77.3%
-9.2% vs industry average
1%
9 trials in Phase 3/4
58%
187 of 324 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (607)
Axitinib + Ipilimumab in Advanced Melanoma
Role: lead
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients
Role: lead
Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery
Role: lead
Smoking Cessation Program for Lao People With HIV
Role: collaborator
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Role: lead
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Role: lead
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Role: lead
Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools
Role: lead
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
Role: lead
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Role: lead
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Role: lead
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Role: collaborator
Mobile Contingency Management for Smoking Cessation
Role: collaborator
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Role: lead
Using Aspirin to Improve Immunological Features of Ovarian Tumors
Role: lead
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
Role: lead
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Role: collaborator
Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients
Role: lead
Digoxin Medulloblastoma Study
Role: lead
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Role: lead